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OnabotulinumtoxinA Injection for Poststroke Upper-Limb
Spasticity: Guidance for Early Injectors From a Delphi
Panel Process
David M. Simpson, MD, Atul T. Patel, MD, Abraham Alfaro, PhD, DO, Ziyad Ayyoub, MD,
David Charles, MD, Khashayar Dashtipour, MD, PhD, Alberto Esquenazi, MD,
Glenn D. Graham, MD, John R. McGuire, MD, Ib Odderson, MD, PhDAbstractBackground: OnabotulinumtoxinA reduces muscle hypertonia associated with poststroke spasticity (PSS). PSS manifests as several
common postures.
Objective: To define treatment paradigms for PSS upper-limb common postures.
Design: Modified Delphi method.
Setting: Expert panel.
Participants: Ten injectors experienced in the treatment and clinical research of PSS (physiatrists and neurologists) were invited
to participate in the Delphi panel.
Methods: The Delphi panel reviewed an electronic worksheet with PSS upper-limb postures to define onabotulinumtoxinA
treatment paradigms (Round 1). During Round 2, panel members discussed in person Round 1 results and voted until consensus
(66% agreement). Recommendations were geared toward those with new or early injection experience.
Main Outcome Measurements: Expert consensus on onabotulinumtoxinA treatment parameters for PSS including muscles to
inject, dose per muscle and posture, and treatment adjustments for suboptimal response.
Results: For each posture, consensus was reached on targeted subsets of muscles. Doses ranged for individual muscles (10-100 U)
and total doses per posture (50-200 U). An onabotulinumtoxinA dilution 50 U/mL (2:1 dilution ratio) was considered most
appropriate; dilution ratios of 1:1 to 4:1 may be appropriate in some circumstances. The majority (89%) of panel members would
increase the dose and/or the number of muscles treated for a suboptimal response to onabotulinumtoxinA. The panel identified 3
common aggregate upper-limb postures: (1) adducted shoulder þ flexed elbow þ pronated forearm þ flexed wrist þ clenched fist;
(2) flexed elbow þ pronated forearm þ flexed wrist þ clenched fist; and (3) flexed wrist þ clenched fist. The recommended
starting dose per aggregate was 300 U, 300 U, and 200 U, with a total maximum dose of 400 U, 400 U, and 300 U, respectively.
Localization guidance techniques were considered essential for all postures.
Conclusions: Consensus on common muscles and onabotulinumtoxinA treatment paradigms for postures associated with upper-
limb PSS was achieved via a modified Delphi method. The purpose of this analysis is to educate early onabotulinumtoxinA
injectors rather than provide an evidence-based review.Introduction
Upper-limb spasticity is characterized by over-
activity in muscles after injury to the central nervous
system. When left untreated, poststroke spasticity
(PSS) can lead to contractures [1], pain and deformity
[2], involuntary movement, and greater functional
impairments (eg, reduced mobility, self-care, dressing)1934-1482 ª 2016 by the American Academy of Physical Medicine and Reha
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.pmrj.2016.06.016and medical complications (eg, skin maceration and
pressure sores) [1]. In patients with PSS, muscle hy-
pertonia typically manifests in several common
postural patterns [3-5], likely because of the location
of the lesion in relation to the descending pathways
controlling spinal reflex excitability [6-9]. These pat-
terns were described in an international, cross-
sectional survey of clinicians in 31 countries [10] andbilitation. This is an open access article under the CC BY-NC-ND license
2 OnabotulinumtoxinA Injection for Upper Limb PSSsubsequently used to develop a classification system
for upper-limb postures [6].
Effective management of spasticity is multifaceted
and should involve the coordinated efforts of an inter-
disciplinary team [1]. Treatment of exacerbating factors
such as skin breakdown, infection, and pain is para-
mount. Rehabilitation therapy and limb positioning to
maintain muscle length and reduce deformity is impor-
tant for the effective management of spasticity.
Adjunctive systemic antispasmodics may be required,
and surgical release of contracture may be indicated if
spasticity is uncontrolled or left untreated. Botulinum
toxins, including onabotulinumtoxinA, have become an
integral part of the treatment paradigm for spasticity
and have proven clinical efficacy in reducing focal
muscle hypertonia [11-22] and improving passive func-
tion (eg, muscle tone and limb position) [23]. Improve-
ments in active function have been observed in case
studies and qualitative retrospective analyses [23,24].
There is still a gap between the existing Class 1 evi-
dence for the clinical efficacy of onabotulinumtoxinA in
reducing upper- and lower-limb PSS and providing cli-
nicians with comprehensive information to effectively
manage their patients with PSS. There is no clear
guideline for an optimal botulinum toxin intervention
regimen, including the frequency of injections (early
versus late), muscle localization technique, injection
sites, dilutions, and doses [25]. This finding is supported
by published studies of botulinum toxin A for PSS that
reported inconsistently the localization of the injection
into each muscle [11-14,26,27] or the number of sites
injected per muscle [11,16,27]. In addition, some
studies did not provide sufficient information on
concomitant therapy (including oral medications, reha-
bilitation, or implantable devices) [11,12,15].
This study was designed for people with new or early
injection experience to bridge portions of this infor-
mation gap via a modified Delphi methodology [28]. This
approach is helpful when the literature contains insuf-
ficient evidence for treatment protocols and when the
evidence requires further review and deliberation by
experts [28]. The Delphi method [29] has been used to
obtain consensus on the use of onabotulinumtoxinA to
treat patients with stroke [30] and overactive bladder
[31] and also on the use of intravenous thrombolytics for
ischemic stroke [32]. We used a modified Delphi method
to obtain insights relevant to the management of pa-
tients with focal upper-limb PSS who were receiving
onabotulinumtoxinA therapy. Other botulinum toxins
were not considered because the potency units are
specific to each botulinum toxin product, and doses or
units of biological activity cannot be compared or con-
verted from one product to any other botulinum toxin
product [33]. The Delphi panel members’ judgments
were collected and applied systematically to define
treatment algorithms for the use of onabotulinumtoxinA
by early injectors for the common postures associatedwith upper-limb spasticity. The emphasis, therefore,
has been focused on treatment individualization rather
than evidence-based clinical trial findings with regard to
the degree and location of the spasticity, the condition
of the patient, and dose limitations.
MethodsDelphi Panel Process
Overview
Ten injectors (physiatrists and neurologists) experi-
enced in the treatment and clinical research of PSS
were invited to participate in the Delphi panel [34]. The
panelists had a mean of 22.0 years of experience in the
treatment and clinical research of PSS. The focus of the
panel was to provide guidance from the perspective of a
new or early injector. A modified panel approach was
used, consisting of 2 formal rounds of feedback with an
allowance for a third round of voting if consensus was
not achieved. The first round was conducted by the use
of a survey, with responses kept anonymous; the second
round was conducted as an in-person Delphi panel.Initial Development of Upper-Limb Common
Postures of Spasticity Picture GuideBefore the Delphi panel, the most common spasticity
postures observed among adult individuals with spas-
ticity were identified by 5 specialists in spasticity,
including 2 of the Delphi panel members (I.O. and K.D.).
Patients with spasticity resulting from stroke or brain or
spinal cord injury were photographed at a rehabilitation
clinic. Although the focus of the Delphi panel was
treatment of PSS, the characteristic postures of spas-
ticity were observed in this population with diverse
etiologies. Initially, clinicians separately ranked the
most representative photo for each posture based on
how well they apply to PSS and the potential need for
treatment. In the final round, a summary of the first-
round results was presented and again ranked. A medi-
cal illustrator converted the most highly ranked photos
into representative sketches to create the draft Com-
mon Postures of Spasticity [35].Delphi Panel: Round 1For Round 1, an e-mail containing 2 worksheets was
sent to the 10 Delphi panel members. The worksheet
contained the Common Postures of Spasticity (Figure 1)
and asked the following questions:
1. Which muscles would you inject with onabotuli-
numtoxinA for a naive patient?
2. What is the total dosage of onabotulinumtoxinA you
would use to treat this posture?
Figure 1. Delphi panel Round 1: example from Common Postures of Spasticity Worksheet. OnabotA, onabotulinumtoxinA.
3D.M. Simpson et al. / PM R XXX (2016) 1-133. How would you distribute the dose among the mus-
cles you selected?
4. If you don’t see optimal efficacy (no safety concern)
after the first treatment, how would you adjust at the
next treatment?
The panel then answered the questions based on the
following patient scenario: an upper-limb PSS patient in
need of onabotulinumtoxinA treatment. The patient had
never received botulinum toxin and had no major safety
concerns. The focus of the panel was from the
perspective of a new or early injector. The worksheet
contained a comment area in which the Delphi panel
members could provide additional feedback (Figure 1).
The second worksheet, Aggregate Postures, con-
tained a listing of the same 7 common postures, and the
panel was asked to rank the 3 most common posture
combinations typically treated together for a patient
with moderate PSS. The panel members could choose
any combination on the basis of their clinical experience
(Figure 2).
Frequency distributions were calculated for muscle-
related questions. For questions related to total ona-
botulinumtoxinA doses and dose per muscle, means,
medians, and ranges were calculated. Data were pre-
sented to the panel during Round 2 as descriptive
summary statistics, with individual responses kept
anonymous. Recommendations for aggregate postureswere rank-ordered, and the top 3 were presented and
discussed during Round 2.Delphi Panel: Round 2Round 2 was an 8-hour, in-person session. Facilitated
by an experienced independent moderator, the panel
focused on the 4 key aspects of the treatment paradigm
for onabotulinumtoxinA and PSS postures: (1) muscles to
be injected, (2) total dose, (3) dose and number of in-
jection sites per muscle, and (4) use of muscle injection
localization techniques. Other treatment elements,
including but not limited to, injection site and onabo-
tulinumtoxinA dilution also were captured, and at a
later date, the injection site voting occurred.
The panel members were asked to consider how they
would treat 80% of their patients when they selected
answers for each posture. The panel also was asked to
consider the onabotulinumtoxinA treatment paradigm
for patients who were treatment-naive and for physi-
cians who were less experienced. Individual treatment
goals [36] and physician’s comfort with injection can
vary considerably, depending on the clinical experience
and the patient’s degree of spasticity. Therefore, spe-
cific treatment paradigms may have considerable vari-
ability among patients on the basis of the specifics of
their spasticity and preclinical evaluation.
Figure 2. Delphi panel Round 1: example from Aggregate Postures Worksheet. *The panel agreed that the prevalence of intrinsic plus hand in their
practices is low (5%-10% of patients). Therefore, the panel agreed to remove the posture from further consideration in Round 2.
4 OnabotulinumtoxinA Injection for Upper Limb PSSThe panel was able to review and discuss the Round 1
results and then vote again for each common posture
treatment paradigm (ie, total dose, muscles injected,
dose per muscle). This session was audio-recorded and
transcribed.
During the first round of voting for each posture,
consensus was defined as 75% agreement. If consensus
was <75%, the item was voted on again. If 66% of panel
members agreed during the second round, the item was
included. If <66% of the panel agreed, the item was
excluded. For total onabotulinumtoxinA dose recom-
mendation, consensus was achieved if66% of the panel
agreed on the same total dose. If <66% of the panel
agreed on a total dose, further discussion would ensue,
and another round of voting would take place until 66%
agreement was reached. The panel members were asked
to distribute the agreed-on total dose among themuscles
for that posture. The dose that received the most votes
was confirmed as the consensus dose for that muscle,
unless there were strong objections from panelists. The
panel was asked to discuss and vote on how they would
adjust their treatment approach if they did not observe
optimal effectiveness after the first treatment (barring
any safety concerns). Finally, the panel was asked to
discuss and vote on those muscles requiring a muscle
localization technique (eg, electromyography [EMG],
electrical stimulation, and ultrasonography).Results
For Round 1, the Common Postures of Spasticity and
Aggregate Postures worksheets were completed by 8 of
10 panelists. Nine of the 10 panelists attended the
Delphi meeting (April 12, 2014, Newport Beach, CA).
The findings from Round 2 for each of the postures arepresented separately below, and the final Common
Postures Picture Guide is shown in Figure 3.Adducted Shoulder With Internal RotationAn initial list of 7 muscles was reduced to 2 during
second round voting. Overall, 75% of the panel agreed
the pectoralis complex and latissimus dorsi should be
targeted for injection (Table 1). The most frequently
recommended total dose of onabotulinumtoxinA was
150 U (range, 100-200 U). During postvoting discussions,
it was mentioned that EMG should be performed to
determine potential involvement of the teres major,
and others cautioned that this is a difficult target for the
less-experienced injector. It was also recommended
that an early injector should not inject the sub-
scapularis, because injecting the other muscles ad-
dresses the spasticity. Overall, the panel felt that for
this posture it was best to limit the number of muscles
injected by the less-experienced injector; however, a
more-experienced injector may feel that targeting more
muscles would likely improve outcomes.Flexed ElbowOf the initial 5 muscles, the list was reduced to 3
after second round voting. Complete consensus was
reached for injection into the brachioradialis, and 75%
agreement was reached for the biceps brachii and bra-
chialis (Table 1). The most frequently recommended
total dose for all 3 muscles was 150 U (range, 100-150
U). During postvoting discussions, the panel noted that
elbow flexion is a critical movement for arm function
and revised the original figure in the assessment tool to
illustrate this (the revised figure is used in this article).
Figure 3. Post-Delphi revisions: final redrawn images for Common Postures of Spasticity Picture Guide: Upper Limb.
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of the amount of onabotulinumtoxinA injected into the
biceps brachii, as the biceps is both a flexor and a su-
pinator muscle. Two panel members indicated that they
do not inject the biceps, or inject low doses, in an effort
to not overweaken supination.Pronated ForearmAn initial list of 5 muscles was reduced to 2; complete
consensus was reached on the pronator quadratus and
pronator teres during second round voting (Table 1). The
most frequently recommended total dose of onabotuli-
numtoxinA was 75 U (range, 50-100 U). In postvoting
discussions, it was noted by some Delphi panel members
that physical exam can help determine if the pronator
quadratus is involved: the elbow can be flexed to see
whether the patient has tightness with supination.Flexed WristAn initial list of 6 muscles was reduced to 2 during
second round voting. Complete consensus was reached
for injection into the flexor carpi radialis and the
flexor carpi ulnaris (Table 1). The most frequently
recommended total dose of onabotulinumtoxinA was
100 U (range, 60-100 U). During postvoting discussions,
it was noted that the dosing for this posture should be
based on the desired function and presentation. The100-U dose is appropriate when attempting to improve
passive function; however, a more conservative
approach with lower doses might be appropriate when
gains in active function (voluntary movement) are the
goal. Thus, one might start with a lower dose (eg,
75 U). In cases where finger flexors contribute to the
flexed wrist posture, these muscles should also be
injected.Flexed FingersAn initial list of 4 muscles was reduced to 2 during
second round voting; complete consensus was reached
for injection into the flexor digitorum superficialis and
flexor digitorum profundus (Table 1). The most
frequently recommended total dose of onabotuli-
numtoxinA was 100 U (range, 50-100 U). During post-
voting discussions, it was noted that involvement of the
flexor digitorum superficialis and the flexor digitorum
profundus almost always occurs together. When making
dosing decisions, the panel felt that consideration for
dose adjustment must be given to whether patients are
using their grip for active function (eg, a patient who
uses a walker for ambulation).Thumb-in-PalmAn initial list of 4 muscles was reduced to 3 after the
second round of voting. Complete consensus was
Table 1
Summary of panel recommendations (round 2)
Adducted Shoulder*
Muscles
Technique and Total DosePectoralis Complex Latissimus Dorsi
Panelists (%) recommending injection of this muscle 87.5 75 LT: yes†
OnabotulinumtoxinA dose, U (mode) 75 75 150
OnabotulinumtoxinA dose, U (range) 75-100 75 100-200
Number of injection sites per muscle 4 4
Flexed Elbow
Muscles
Technique and Total DoseBrachioradialis Biceps Brachii Brachialis
Panelists (%) recommending injection of this muscle 100 87.5 75 LT: yes†
OnabotulinumtoxinA dose, U (mode) 25 50 75 150
OnabotulinumtoxinA dose, U (range) 25-50 0-50 50-100 100-150
Number of injection sites per muscle 2 4 2
Pronated Forearm
Muscles
Pronator Quadratus Pronator Teres Technique and Total Dose
Panelists (%) recommending injection of this muscle 100 100 LT: yes†
OnabotulinumtoxinA dose, U (mode) 25 50 75
OnabotulinumtoxinA dose, U (range) 0-25 45-60 50-100
Number of injection sites per muscle 1 2
Muscles
Flexed Wrist Flexor Carpi Radialis Flexor Carpi Ulnaris Technique and Total Dose
Panelists (%) recommending injection of this muscle 100 100 LT: yes†
OnabotulinumtoxinA dose, U (mode) 50 50 100
OnabotulinumtoxinA dose, U (range) 50-75 25-50 60-100
Number of injection sites per muscle 2 2
Flexed Fingers
Muscles
Technique and Total Dose
Flexor Digitorum
Superficialis
Flexor Digitorum
Profundus
Panelists (%) recommending injection of this muscle 100 100 LT: yes†
OnabotulinumtoxinA dose, U (mode) 50 50 100
OnabotulinumtoxinA dose, U (range) 20-60 25-75 50-100
Number of injection sites per muscle 2 2
Thumb-in-palm
Muscles
Technique and Total Dose
Flexor Pollicis
Longus
Adductor
Pollicis
Flexor Pollicis
Brevis
Panelists (%) recommending injection of this muscle 100 87.5 87.5 LT: yes†
OnabotulinumtoxinA dose, U (mode) 40 15 20 75
OnabotulinumtoxinA dose, U (range) 40-50 10-20 12.5-20 50-75
Number of injection sites per muscle 2 1 1
Clenched Fist
Muscles
Technique and
Total Dose
Flexor Digitorum
Superficialis
Flexor Digitorum
Profundus
Flexor Pollicis
Brevis
Flexor Pollicis
Longus
Adductor Pollicis
Longus
Panelists (%) recommending injection
of this muscle
100 100 75 100 75 LT: yes†
OnabotulinumtoxinA dose, U (mode) 50 50 15 25 10 150
OnabotulinumtoxinA dose, U (range) 40-50 25-60 10-15 25-30 10-12.5 125-175
Number of injection sites per muscle 2 2 1 2 1
LT ¼ Localization technique.
* The Delphi panel only reached consensus on these 2 muscles (pectoralis complex and latissimus dorsi) for the adducted shoulder with internal
rotation as the goal was to provide common postures for inexperienced injectors, and the panel felt that the other muscles might be too difficult
for someone without more substantial injection experience. They do agree that an experienced injector would most likely inject more muscles.
† All of the Delphi panel members voted that using a localization technique (electromyography, electrical stimulation, or ultrasound) was critical
for all postures.
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longus); 87.5% agreed on the adductor pollicis and flexor
pollicis brevis (Table 1). The most frequently recom-
mended total dose of onabotulinumtoxinA was 75 U
(range, 50-75 U). During postvoting discussions, a panel
member noted the importance of aggressive treatment,
as patients with this posture often have little to no hand
function.Clenched FistAn initial list of 8 muscles was reduced to 5 after
a second round of voting. Complete consensus
(100% agreement) was reached for 3 of the 5 muscles
involved (flexor digitorum superficialis, flexor dig-
itorum profundus, flexor pollicis longus); 75% agree-
ment was attained for the other 2 muscles (Table 1).
The most frequently recommended total dose of ona-
botulinumtoxinA was 150 U (range, 125-175 U). During
the postvoting discussion of the clenched fist, it was
noted that the opponens pollicis and flexor pollicis
brevis were major contributors to the thumb-in-palm
posture, but that the opponens pollicis was not a
major contributor to the clenched fist deformity.Aggregate PosturesDuring Round 1, the 3 most commonly selected
upper-limb aggregate postures were discussed. The
panel agreed that it would be of value to gain
consensus on the recommended starting dose and the
maximum total dose of onabotulinumtoxinA for each
aggregate posture combination. The final results of
these discussions are summarized in Table 2. Some
panel members noted that for less-experienced in-
jectors treating naive patients, 400 U is the maximum
dose that should be used for aggregate upper-limb
postures. The dose should be reduced if there is
excessive weakness. Less-experienced injectors should
talk to their patients about which postures, in complex
combinations, might benefit from treatment, and thenTable 2
Three most common aggregate postures
Aggregate Postures
Starting Dose
(Typical)
Total Dose
(Maximum)
1 Adducted shoulder 300 U 400 U
Flexed elbow
Pronated forearm
Flexed wrist
Clenched fist
2 Flexed elbow 300 U 400 U
Pronated forearm
Flexed wrist
Clenched fist
3 Flexed wrist 200 U 300 U
Clenched fistuse the minimum recommended dose based on those
postures. Preservation of active function is an impor-
tant consideration when making dosing decisions for
aggregate postures.
During Round 2, all panel members agreed that
localization technique for onabotulinumtoxinA injection
is critical. When asked how they would adjust a second
treatment if they did not observe optimal effectiveness
after the first injection with onabotulinumtoxinA, 8 of
the 9 panelists responded that they would increase the
dose and/or the number of muscles they would inject
for that posture.Other Treatment ConsiderationsSafety issues described in the U.S. Food and Drug
Administration (FDA)-approved prescribing information
for onabotulinumtoxinA were acknowledged, but spe-
cific management of potential adverse events was
beyond the scope of this panel. Clinical experience
should guide treating physicians on appropriate adverse
event management. In addition, clinicians should
consider local approved prescribing information for
dosing guidelines (ie, the U.S. FDA-approved labeling for
onabotulinumtoxinA states a maximum dose of 400 U
per 3-month interval). The panel agreed that the rec-
ommendations on optimal technique for each group of
target muscles should mitigate risks related to inap-
propriate dosing and inadvertent injection of the
incorrect muscle(s) or adjacent structures (eg, blood
vessels, nerves, pleural cavity).
Although the worksheets were developed to target
less-experienced injectors, and the Delphi panel
members were instructed to complete the worksheets
with these health care professionals in mind, the
panel noted that it would be of value to expand the
targeted audience to include experienced injectors.
During panel voting discussions, panelists strongly
agreed that treatment insights, treatment techniques,
and expertise were enhanced by experienced
clinicians.
The panel also noted that treatment algorithms
should include consideration of active function. Defining
expected treatment outcomes for a patient with PSS is
an essential component of injector training. Dosing de-
cisions are made, at least in part, on an assessment of
functional needs: those that already exist or that need
to be achieved. Understanding passive and active
function is important in goal-setting [37].
An onabotulinumtoxinA dilution of 50 U/mL (2:1
dilution ratio) was considered most appropriate (dilu-
tion ratios of 1:1 to 1:4 were appropriate in some cases)
and recommended for patients with PSS in the scenario
presented for the exercise. However, although 2:1 was
appropriate for this exercise, in practice an injector
might vary the dilution based on the muscles involved.
In clinical practice, several factors are involved in
Table 3
Summary of Delphi panel recommendations from Round 1 (italics)* and Round 2 (bolded)* and comparison with other published recommendations
Posture Muscles
Total Dose, U
Adducted Shoulder
With Internal Rotation†
Pectoralis
Complex
Latissimus
Dorsi
Teres
Major Subscapularis Deltoid Media Brachialis
Levator
Scapulae
Muscle frequency 87.5% 75% 75% 50% 12.5% 12.5% 12.5%
OnabotulinumtoxinA
dose, U (mode)
75 75 150
OnabotulinumtoxinA
dose, U (range)
75-100 75 50-75 75 20 75 38 100-200
Muscles Included for Injection in Published Algorithms/Recommendations
Citation
Brin 1997 [3] X X X X
Mayer et al 1997 [5] X X X X
Royal College of
Physicians 2009 [4]
X X X X X Rhomboids
Sheean et al 2010 [25] X X X X X
Flexed Elbow Brachioradialis
Biceps
Brachii Brachialis
Pronator
Teres
Pronator
Quadratus
Muscle frequency 100% 87.5% 75% 50% 12.5%
OnabotulinumtoxinA
dose, U (mode)
25 50 75 150
OnabotulinumtoxinA
dose, U (range)
25-50 0-50 50-100 38-100 N/A 100-150
Muscles Included for Injection in Published Algorithms/Recommendations
Citation
Brin 1997 [3] X X X
Mayer et al 1997 [5] X X X
Royal College of
Physicians 2009 [4]
X X X
Sheean et al 2010 [25] X X X X FCR
Pronated Forearm
Pronator
Quadratus
Pronator
Teres FCU Brachialis Brachioradialis
Muscle frequency 100% 100% 12.5% 12.5% 12.5%
OnabotulinumtoxinA
dose, U (mode)
25 50 75
OnabotulinumtoxinA
dose, U (range)
0-25 45-60 20 100 25 50-100
8
O
n
a
b
o
tu
lin
u
m
to
xin
A
In
je
ctio
n
fo
r
U
p
p
e
r
Lim
b
P
SS
Muscles Included for Injection in Published Algorithms/Recommendations
Citation
Brin 1997 [3] X X
Mayer et al 1997 [5] X X
Royal College of
Physicians 2009 [4]
X X
Sheean et al 2010 [25] X X X
Flexed Wrist FCR FCU
Palmaris
Longus
Flexor Pollicis
Longus
Flexor Digitorum
Superficialis
Flexor Digitorum
Profundus
Muscle frequency 100% 100% 50% 25% 50% 37.5%
OnabotulinumtoxinA
dose, U (mode)
50 50 100
OnabotulinumtoxinA
dose, U (range)
50-75 25-50 13-50 20-75 25-75 25-75 60-100
Muscles Included for Injection in Published Algorithms/Recommendations
Citation
Brin 1997 [3] X X
Mayer et al 1997 [5] X X X Flexor carpus
radialis and brevis
Royal College of
Physicians 2009 [4]
X X X X X
Sheean et al 2010 [25] X X
Flexed fingers‡
Flexor
Digitorum
Superficialis
Flexor
Digitorum
Profundus FCR/FCU Lumbricales
Muscle frequency 100% 100% 12.5% 12.5%
OnabotulinumtoxinA
dose, U (mode)
50 50 100
OnabotulinumtoxinA
dose, U (range)
20-60 25-75 30 30 50-100
Posture Muscles
Thumb-in-palm
Flexor Pollicis
Longus
Adductor
Pollicis
Flexor Pollicis
Brevis
Flexor Digitorum
Profundus
Muscle frequency 100% 87.5% 87.5% 12.5%
OnabotulinumtoxinA
dose, U (mode)
40 15 20 75
OnabotulinumtoxinA
dose, U (range)
40-50 10-20 12.5-20 35 50-75
Muscles Included for Injection in Published Algorithms/Recommendations
Citation
Brin 1997 [3] X X Opponens pollicis
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10 OnabotulinumtoxinA Injection for Upper Limb PSSdetermining the dilution ratio, including the posture,
muscle size, location of motor endplates, to the limited
extent that they are known, intended injection location
relative to neighboring structures, EMG activity, previ-
ous interventions, and level of experience of the
treating clinician [38,39].
Some panelists noted that the common postures
treatment algorithms may be more informative if they
provided dosing ranges rather than discrete amounts for
each posture’s total dose and dose per muscle, as the
presentation of PSS may vary during the treatment
period. The panelists also summarized the number of
injection sites needed per upper-limb muscle, regard-
less of the posture that was being presented (Table 1).
Almost all panelists (88.9%) agreed to increase the dose,
increase the number of muscles treated, and/or modify
the dilution at the next visit if suboptimal efficacy (with
no safety concerns) was observed.
Discussion
In this study, we used a modified Delphi method to
obtain consensus-based recommendations on onabotu-
linumtoxinA treatment paradigms for upper-limb com-
mon postures in patients with PSS and to develop
guidance for clinicians, especially those with limited
injection experience, toward the application of indi-
vidualized onabotulinumtoxinA treatment paradigms
for PSS. The goal was to fill an educational gap and
provide practicing clinicians with no or very little in-
jection experience with guidance on how to effectively
manage their patients with PSS. The panel agreed that
injection localization techniques are essential for each
muscle involved, concurred on the 3 most common
aggregate posture combinations, and agreed on the
typical starting dose and maximum total dose for each
combination. Because these recommendations were
intended to guide injectors with limited or no injection
experience, certain muscles that require a high level of
skill, such as the subscapularis and hand intrinsics,
were excluded.
Beyond the original worksheet content, panel mem-
bers expressed interest reaching consensus on an ona-
botulinumtoxinA dilution ratio. The discussion focused
on a number of contributing factors, including muscle
size, the etiology of the spasticity, total dose, injection
technique, chronicity, and the presence of contrac-
tures, as well as the level of experience of the treating
physician. Ultimately, it was decided that a 2:1 dilution
ratio was appropriate in the context of the exercise and
the patient scenario provided, although that dilution
ratio might vary based on the clinical presentation and
experience of the injector.
Notably, the FDA has included in the labeling of all
formulations of botulinum toxins that they are not
interchangeable, and units cannot be converted using
a dose ratio. Therefore, the recommendations are
11D.M. Simpson et al. / PM R XXX (2016) 1-13specific to onabotulinumtoxinA, and the conclusions
reported here should not be extrapolated to other
botulinum toxin formulations.
The panel emphasized that the effects of PSS, and
the treatment thereof, should be considered with re-
gard to the level of impairment (eg, hypertonicity,
limb deformity) and the impact on functiondactive
and passive [36]. One advantage of onabotulinumtox-
inA is that it can reduce local muscle overactivity,
without an impact on cognition or alertness, and usu-
ally without creating generalized weakness, or other
significant adverse effects. Nevertheless, to date,
limited data support a benefit of botulinum toxin on
active function in patients with upper-limb spasticity,
with inconsistent results in both controlled and open-
label studies [23-25]. The authors and clinical experts
agree that future study designs may fill these data
gaps [40].
Recommendations generated during the Delphi pro-
cess are not designed to supersede evidence-based
treatment guidelines, peer-to-peer training, clinical
judgment, particularly that of experienced physicians,
or clinical research. Randomized controlled trials are
the gold standard, but their strict protocols may not
allow an individualized patient approach or treatment
interventions applicable to many clinical scenarios.
Thus, many research findings generated from placebo-
controlled trials do not adequately guide treatment
for the entire PSS patient population.
The Delphi approach helps bridge some of these
gaps. Not surprisingly, the panel’s recommendations
are in concordance with previously published treat-
ment algorithms [3,5] and clinical guidelines
[1,2,4,25,41-43]. This study specifies the particular
muscles involved in common postures associated with
upper-limb spasticity, details the importance of local-
ization, and suggests onabotulinumtoxinA dosing and
dilution ratios.
As summarized in Table 3, there is large overlap
between published guidelines and the panel’s final
recommendations with regard to the muscles for
onabotulinumtoxinA injection associated with each
posture. This is particularly noteworthy for the clenched
fist, flexed elbow, and pronated forearm postures. By
contrast, for the adducted shoulder with internal rota-
tion, the Delphi panel agreed to inject the pectoralis
complex and latissimus dorsi, as they were concerned
that less-experienced injectors may have difficulty
injecting some of the other affected muscles initially
identified. Previous published reports also included the
teres major and subscapularis [3-5,25]. The variability in
the recommendations is partially based on the directives
of the Delphi panel to consider early injectors. Indeed,
more-experienced injectors may be also comfortable
injecting the teres major and subscapularis when
presented with a patient with adducted shoulder and
internal rotation.Conclusions
This study used a modified Delphi method with a
10-member panel of physiatrists and neurologists with
expertise in botulinum toxin injection and research
methodology to determine clinical recommendations for
treating upper-limb spasticity in patients with PSS with
onabotulinumtoxinA. Treatment algorithms for 7 com-
mon postures were developed, as were 3 common
aggregate postures and included the specific muscles to
be injected, the total dose per muscle and posture,
dilution ratio, and the use of localization techniques to
identify target muscles for injection. Posture pictures
were developed to delineate limb position and muscle
involvement.
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